Peptides derived from human immunodeficiency virus-1 GP160

Details Peptides derived from human immunodeficiency virus-1 GP160 Peptides derived from human immunodeficiency virus-1 GP160

1992-10-19

1994-08-16

Nucker, Christine M.

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

530325, 530350, A61K 3702, C07K 300, C07K 500, C07K 1500

Patent

active

053388291

ABSTRACT:
This invention discloses novel polypeptides having an antigenic determinant or determinants immunologically cross-reactive with determinants of a glycoprotein having a molecular weight of approximately 41,000 daltons, and determinants of a glycoprotein having a molecular weight of approximately 160,000 daltons which are obtained from cells infected with human immunodeficiency virus-1. The invention further discloses novel polypeptides having an antigenic determinant or determinants specific for a glycoprotein having a molecular weight of approximately 41,000 daltons obtained from cells infected with human immunodeficiency virus-1, the polypeptides further having an antigenic determinant or determinants immunologically cross-reactive with at least one glycoprotein having a molecular weight of 25,000 to 35,000 daltons, 45,000 daltons to 60,000 daltons, 80,000 to 100,000 daltons or 180,000 or 220,000 daltons, which are obtained from HSB, St, HeLa and human cells. The novel polypeptides of the invention are useful in methods of interfering with the effects of HIV-1 upon host cells having cell surface polypeptides capable of binding HIV-1. Methods of assay for HIV-1 infection are also disclosed. The invention also discloses peptides having amino acid sequences of about 10 to about 50 amino acids that correspond to at least a portion of an epitope of HIV and methods for developing such biologically active peptides.

REFERENCES:
patent: 4490358 (1984-12-01), Greene et al.
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4722888 (1988-02-01), Broder et al.
patent: 4725669 (1988-02-01), Essex et al.
patent: 4743678 (1988-05-01), Essex et al.
Zhou et al., The Journal of Immunology, 139(9):2950-2956 (1987).
Wang et al., Proceeding of the National Academy of Science, U.S.A., 83:6159-6163 (1986).
McDougal et al., The Journal of Immunology, 137(9):2937-2944 (1986).
Sattentau et al., Science, 234:1120-1123 (1985).
Chanh et al., Proceedings of the National Academy of Science, U.S.A., 84:3891-3895 (1987).
Banapour et al., The Journal of Immunology, 139:4027-4033 (1987).
Dalgleish et al., Nature, 312:763-767 (1984).
Sodroski et al., Nature, 322:470-474 (1984).
McCune et al., Cell, 53:55-67 (1988).
Burstin et al., Virology, 117:146-155 (1982).
International Search Report for application Ser. No. PCT/US89/01621.
Chiodi et al., Journal of Medical Virology 23:1-9 (1987).
Gnann et al., Journal Inf. Dis. 156(2):261-267 (1987).
Ho et al., Journal of Virol., 61(6):2024-2028 (1987).

Affiliated with

Also associated with

Rating

Peptides derived from human immunodeficiency virus-1 GP160 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides derived from human immunodeficiency virus-1 GP160, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides derived from human immunodeficiency virus-1 GP160 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-952860